Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aeterna Zentaris stock

AEZS.TO
CA0079754028
A1439Z

Price

3.69
Today +/-
-0.03
Today %
-1.00 %
P

Aeterna Zentaris stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aeterna Zentaris stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aeterna Zentaris stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aeterna Zentaris stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aeterna Zentaris's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aeterna Zentaris Stock Price History

DateAeterna Zentaris Price
10/3/20243.69 undefined
10/2/20243.73 undefined
10/1/20243.84 undefined
9/30/20243.72 undefined
9/27/20243.85 undefined
9/26/20243.96 undefined
9/25/20243.86 undefined
9/24/20243.72 undefined
9/23/20243.79 undefined
9/20/20244.10 undefined
9/19/20244.10 undefined
9/18/20244.04 undefined
9/17/20244.10 undefined
9/16/20244.27 undefined
9/13/20244.19 undefined
9/12/20243.97 undefined
9/11/20244.09 undefined
9/10/20244.11 undefined
9/9/20244.12 undefined
9/6/20244.00 undefined
9/5/20243.74 undefined

Aeterna Zentaris Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aeterna Zentaris, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aeterna Zentaris from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aeterna Zentaris’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aeterna Zentaris. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aeterna Zentaris’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aeterna Zentaris’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aeterna Zentaris’s growth potential.

Aeterna Zentaris Revenue, EBIT and net profit per share

DateAeterna Zentaris RevenueAeterna Zentaris EBITAeterna Zentaris Net Income
2025e8.15 M undefined-3.36 M undefined-1.98 M undefined
2024e4.39 M undefined-17.22 M undefined-12.72 M undefined
20234.5 M undefined-18.01 M undefined-16.55 M undefined
20225.6 M undefined-15.2 M undefined-22.7 M undefined
20215.3 M undefined-8.7 M undefined-8.4 M undefined
20203.7 M undefined-6.1 M undefined-5.1 M undefined
2019500,000 undefined-9.5 M undefined-6 M undefined
201826.9 M undefined9.8 M undefined4.2 M undefined
2017900,000 undefined-23.1 M undefined-16.8 M undefined
2016900,000 undefined-29.5 M undefined-25 M undefined
2015500,000 undefined-34.9 M undefined-50.1 M undefined
20140 undefined-34.9 M undefined-16.6 M undefined
20136.2 M undefined-27.5 M undefined6.8 M undefined
20122.1 M undefined-29.7 M undefined-20.4 M undefined
20114.7 M undefined-31.7 M undefined-27.1 M undefined
201027.7 M undefined-24.8 M undefined-28.5 M undefined
200963.2 M undefined-24 M undefined-24.7 M undefined
200838.5 M undefined-62.4 M undefined-59.8 M undefined
200741.3 M undefined-34.9 M undefined-33.1 M undefined
200638.8 M undefined-23.8 M undefined33.4 M undefined
200544.8 M undefined-9 M undefined10.6 M undefined
200433 M undefined-5.3 M undefined-3.4 M undefined

Aeterna Zentaris Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e
242452864118334438413863274260000260355448
-100.00-50.00100.0025.00460.00128.5784.38-72.0333.33-13.647.89-7.3265.79-57.14-85.19-50.00200.00-------66.67--20.00-100.00
-100.00100.0075.0080.0028.5723.4440.6878.7981.8271.0568.2950.0073.0233.33100.0050.00100.00----92.31-33.33100.00100.00100.00--
042348154826362728194694160000240155400
-2-1-4-3-8-11-13-10-5-9-23-34-62-24-24-31-29-27-34-34-29-239-9-6-8-15-18-17-3
-100.00-25.00-200.00-75.00-160.00-39.29-20.31-8.47-15.15-20.45-60.53-82.93-163.16-38.10-88.89-775.00-1,450.00-450.00----34.62--200.00-160.00-300.00-450.00-425.00-37.50
00-2-2-6-2-16-20-31033-33-59-24-28-27-206-16-50-25-164-6-5-8-22-16-12-1
----200.00-66.67700.0025.00-85.00-433.33230.00-200.0078.79-59.3216.67-3.57-25.93-130.00-366.67212.50-50.00-36.00-125.00-250.00-16.6760.00175.00-27.27-25.00-91.67
00000000000000000000.10.40.60.70.71.64.64.91.2100
------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Aeterna Zentaris Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aeterna Zentaris is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                       
24.42820.826.845.83451.949.648.334.960.541.449.738.133.946.939.543.234.941.5227.814.57.824.365.350.634.02
0.82.82.12.40.912.319.732.843.29.66.86.23.42.44.67.77.31.70.60.60.200.10.21.20.90.40.07
0.90.90.80.53.13.327.94.45.32.33.731.21.10.80.60.70.30.300.20.20.20.51.12.81.80.28
0.40.80.90.81.75.210.412.517.85.555.43.44.43.33.54.100000.60.21.200.10.20.07
0.200.10.20.40.72.44.65.8111.425.73.642.91.11.51.70.50.40.30.40.71.21.211.82.51.94
26.732.524.730.751.955.5112.3103.9120.4163.7101.759.661.748.943.760.253.345.736.242.422.89.316.210.927.670.955.536.37
0.51.2610.6109.713.815.116.514.1137.56.74.43.12.52.11.40.80.30.20.10.10.60.20.20.20.32
000000000057.100000000000000000
00000000000000000000000002.81.760
000041.357.450.562.841.437.430.423.9173.31.81.10.70.40.20.10.10.100.10.600
00000.913.915.447.271.69.89.510.510.110.210.410.110.39.98.78.48.18.88.28.18.88.100
0.20.40.70.80.4411.611.419.1190.94.815.465.60.80.80.81.61.40.30.53.90.40.40.30.30.30.33
0.71.66.711.415.328.998.2124.2170256.2121.863.846.737.217.615.214.313.611.39.28.912.98.89.19.4122.260.65
27.434.131.442.167.284.4210.5228.1290.4419.9223.5123.4108.486.161.375.467.659.347.551.631.722.225203782.957.7637.02
                                                       
25.231.830.241.853.461.397.7144.7157.4130.3168.530.630.641.260.9101.9122.8134.1150.5204.6214222.3222.3224.5235293.4293.4293.41
0000000.55.87.300002.9000000000000090.71
1.31.3-1.3-4.1-10.4-12-28.5-56.3-65.5-43.2-10.1-43-102.8-127.5-160.6-189-213.1-203.9-222.3-271.6-298.1-314.2-309.8-316.9-310.3-329.5-347-364.75
000000.10.53.10.922.420.510193.792.782.182.583.686.986.388.690.38989.489.988.589.189.4-1.18
0000000000000000000000000000
26.533.128.937.74349.470.297.3100.1109.5178.988.621.59.3-17.6-4.6-6.717.114.521.66.2-2.91.9-2.513.25335.818.2
0.81.12.31.71.311.217.225.6244711.410.38.26.48.16.74.83.24.221.21.31.11.20.921.87
00002.63.56.110.39.32.92.84.73.43.82.94.23.822.301.41.60.90.911.71.81.76
00000.4031.48.616.756.65.95.48.47.355.65.20.42.12.30.833.432.453.10.76
00000027.4000000000000000000000
00000.22.222.910.10.70.70.800.10.10.100000000.60.10.10.10.16
0.81.12.31.74.516.984.147.460.164.216.422.322.119.414.41815.77.27.66.54.25.85.65.64.77.774.54
000.32.73.26.56.32753.429.90.700.20.10.1000000000.3000.10.12
00000022.42020.48.610.400000000000000000
000016.40.111.813.327.5207.617.312.564.557.664.66258.734.925.423.521.219.217.516.51919.313.114.16
000.32.719.66.640.560.3101.3246.128.412.564.757.764.76258.734.925.423.521.219.217.516.81919.313.214.28
0.81.12.64.424.123.5124.6107.7161.4310.344.834.886.877.179.18074.442.1333025.42523.122.423.72720.218.82
27.334.231.542.167.172.9194.8205261.5419.8223.7123.4108.386.461.575.467.759.247.551.631.622.12519.936.9805637.02
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aeterna Zentaris provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aeterna Zentaris's financial health and stability.

Assets

Aeterna Zentaris's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aeterna Zentaris must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aeterna Zentaris after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aeterna Zentaris's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
00-2-2-6-2-16-20-81033-32-59-24-28-26-23-27-17-50-24-164-6-5-8-22
0000011645857101110000000000
00000-311-40-29-1000000000-330000
0-2001-1-2-1-44040-16-73-3-7-1-30-21-2001
00000-42319-8-5-15062-4-513-1319-30-2-20-17
000000000000000000000000000
000000132050000000000000110
0-1-1-1-4-10-13-107127-25-1-24-31-26-30-19-31-33-29-226-10-4-8-13
00-4-500-4-1-1-1-1-3-100000000000000
0-61-7-213-494-23-95-182642-10200000000000
0-55-1-203-455-21-93-16304300300000000000
000000000000000000000000000
00020-125-90000000000000000000
108010141237260000014263824232449980523540
10701126963121988-8-1-114263824232440980320510
000011-10-31889-700000000-80000-2-30
000000000000000000000000000
10003030743-17038-11-614-73-86-19-146-61641-14
-0.57-2.8-5.98-7.1-4.94-10.83-18.14-11.666.3211.266.11-29.3-2.48-24.93-31.79-27.05-31.09-20.07-31.21-33.87-29.08-22.916.82-10.73-4.13-9.22-13.69
000000000000000000000000000

Aeterna Zentaris stock margins

The Aeterna Zentaris margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aeterna Zentaris. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aeterna Zentaris.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aeterna Zentaris's sales revenue. A higher gross margin percentage indicates that the Aeterna Zentaris retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aeterna Zentaris's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aeterna Zentaris's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aeterna Zentaris's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aeterna Zentaris. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aeterna Zentaris's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aeterna Zentaris Margin History

Aeterna Zentaris Gross marginAeterna Zentaris Profit marginAeterna Zentaris EBIT marginAeterna Zentaris Profit margin
2025e95.06 %-41.21 %-24.32 %
2024e95.06 %-392.6 %-289.98 %
202395.06 %-400.36 %-367.99 %
202298.21 %-271.43 %-405.36 %
202198.11 %-164.15 %-158.49 %
202035.14 %-164.86 %-137.84 %
201920 %-1,900 %-1,200 %
201892.19 %36.43 %15.61 %
201795.06 %-2,566.67 %-1,866.67 %
201695.06 %-3,277.78 %-2,777.78 %
2015100 %-6,980 %-10,020 %
201495.06 %0 %0 %
201398.39 %-443.55 %109.68 %
201271.43 %-1,414.29 %-971.43 %
201195.74 %-674.47 %-576.6 %
201032.49 %-89.53 %-102.89 %
200973.89 %-37.97 %-39.08 %
200849.87 %-162.08 %-155.32 %
200768.77 %-84.5 %-80.15 %
200670.88 %-61.34 %86.08 %
200581.7 %-20.09 %23.66 %
200481.52 %-16.06 %-10.3 %

Aeterna Zentaris Stock Sales Revenue, EBIT, Earnings per Share

The Aeterna Zentaris earnings per share therefore indicates how much revenue Aeterna Zentaris has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aeterna Zentaris earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aeterna Zentaris's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aeterna Zentaris’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aeterna Zentaris's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aeterna Zentaris Revenue, EBIT and net profit per share

DateAeterna Zentaris Sales per ShareAeterna Zentaris EBIT per shareAeterna Zentaris Earnings per Share
2025e2.2 undefined0 undefined-0.54 undefined
2024e1.19 undefined0 undefined-3.44 undefined
20233.71 undefined-14.83 undefined-13.63 undefined
20221.14 undefined-3.1 undefined-4.63 undefined
20211.15 undefined-1.89 undefined-1.83 undefined
20202.31 undefined-3.81 undefined-3.19 undefined
20190.71 undefined-13.57 undefined-8.57 undefined
201838.43 undefined14 undefined6 undefined
20171.5 undefined-38.5 undefined-28 undefined
20162.25 undefined-73.75 undefined-62.5 undefined
20155 undefined-349 undefined-501 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined

Aeterna Zentaris business model

Aeterna Zentaris Inc. is a Canadian company that has been operating in the pharmaceutical industry since 1991. The company is headquartered in Quebec City, Canada and focuses on the development and commercialization of drugs for the treatment of cancer and hormonal disorders. The company started as a small biotech company called "Aeterna Laboratories" that focused on the research of growth hormones and hormonal disorders. In the late 90s, it merged with a German company called "Zentaris GmbH" that specialized in medical diagnostics and chemicals, creating Aeterna Zentaris AG, which was later renamed Aeterna Zentaris Inc. The company has acquired several companies and expanded its portfolio of drugs and treatment options. Aeterna Zentaris is a biopharmaceutical company engaged in preclinical and clinical development of therapeutics. The company's main strategy is to develop and promote innovative and differentiating drug candidates. It works closely with leading academic institutions, researchers, and other companies to advance the development of its products. Aeterna Zentaris has a diversified portfolio of drug candidates in various stages of clinical development. It has two main divisions: cancer treatment and hormonal disorders. The company focuses on developing cancer therapeutics for various types of cancers and also on the treatment of hormonal disorders, including diabetes, growth problems, hormonally related cancers, and menopause. Some of the company's important products include Macrilen, which is used for diagnosing growth hormone deficiency, Zoptrex, which is intended for the treatment of endometrial cancer, and Perifosine, a drug candidate for advanced colorectal cancer. Aeterna Zentaris has established itself as a leading biotech company in the field of cancer and hormone therapy. It has a diverse portfolio of drug candidates in different stages of clinical development. The company collaborates with researchers, medical institutions, and other companies to develop innovative and differentiating drug candidates. Aeterna Zentaris is one of the most popular companies on Eulerpool.com.

Aeterna Zentaris Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Aeterna Zentaris Revenue by Segment

Segmente202320222021
Development services [member]-3.62 M USD-
Development Services Novo Amendment--3.34 M USD
License fees [member]-1.7 M USD-
License Novo Amendment--1.67 M USD
Novo Supply Agreements--185,000 USD
Supply chain [member]-161,000 USD-
Royalties [member]-101,000 USD-
Royalties Novo Amendement--68,000 USD
Product sales [member]-57,000 USD-
Switzerland-5.4 M USD-
Denmark-160,000 USD-
Ireland-82,000 USD-
Other-3,000 USD-
Switzerland--5.08 M USD
Switzerland [member]4.32 M USD--
Denmark--185,000 USD
Ireland [member]122,000 USD--
Other [member]48,000 USD--
Denmark [member]11,000 USD--

Aeterna Zentaris SWOT Analysis

Strengths

Aeterna Zentaris Inc, a specialty biopharmaceutical company, possesses several strengths that contribute to its competitive advantage in the market:

  • Strong portfolio of innovative drug candidates.
  • Expertise in oncology and endocrinology therapeutic areas.
  • Well-established relationships with key stakeholders including physicians, hospitals, and regulatory bodies.
  • Robust intellectual property portfolio protecting its products.
  • Successful history of bringing products to market.

Weaknesses

Despite its strengths, Aeterna Zentaris Inc also faces certain weaknesses that may hinder its growth:

  • High dependence on a limited number of drug candidates.
  • Relatively small scale compared to larger pharmaceutical companies, limiting resources and reach.
  • Significant competition from well-established market players.
  • Reliance on external partnerships for drug development and commercialization.

Opportunities

Market trends and external factors offer opportunities for Aeterna Zentaris Inc to capitalize on:

  • Increasing demand for oncology and endocrinology therapeutics.
  • Advancements in technology and research facilitating drug discovery and development.
  • Expansion into emerging markets with growing healthcare spending.
  • Potential for strategic collaborations and partnerships to enhance product pipeline.

Threats

Aeterna Zentaris Inc must also be mindful of potential threats that could negatively impact its business:

  • Stringent regulations and lengthy approval processes for new drugs.
  • Increased competition from generics and biosimilars.
  • Market volatility and economic uncertainties affecting healthcare spending.
  • Risks associated with clinical trials and drug development failures.

Aeterna Zentaris Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aeterna Zentaris historical P/E ratio, EBIT multiple, and P/S ratio

Aeterna Zentaris shares outstanding

The number of shares was Aeterna Zentaris in 2023 — This indicates how many shares 1.214 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aeterna Zentaris earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aeterna Zentaris's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aeterna Zentaris’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aeterna Zentaris's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aeterna Zentaris stock splits

In Aeterna Zentaris's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Aeterna Zentaris.

Aeterna Zentaris latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2023-3.96 -4.64  (-17.24 %)2023 Q4
9/30/2023-2.49 -3.4  (-36.61 %)2023 Q3
6/30/2023-3.55 -2.08  (41.4 %)2023 Q2
3/31/2023-1.09 -0.88  (19.37 %)2023 Q1
12/31/2022-0.95 -0.87  (8.29 %)2022 Q4
9/30/2022-0.69 -0.7  (-0.92 %)2022 Q3
6/30/2022-0.69 -0.87  (-25.43 %)2022 Q2
3/31/2022-0.51 -0.5  (1.96 %)2022 Q1
12/31/2021-0.51 -0.5  (1.96 %)2021 Q4
9/30/2021-0.51 -0.25  (50.98 %)2021 Q3
1
2
3
4
5
...
7

Aeterna Zentaris shareholders

%
Name
Stocks
Change
Date
4.53597 % Gagnon (Gilles R)167,831167,8312/9/2024
0.43351 % Morgan Stanley & Co. LLC16,040012/31/2023
0.27032 % Citadel Advisors LLC10,00210,00212/31/2023
0.25914 % Li (William W. M.D.)9,5889,5882/9/2024
0.19981 % Kosciessa (Ulrich)7,3937,3932/9/2024
0.11351 % Paulini (Klaus)4,200012/31/2023
0.10811 % Edmond de Rothschild Asset Management (France) S.A.4,000012/31/2023
0.09889 % Geode Capital Management, L.L.C.3,65902/29/2024
0.08105 % Group One Trading, L.P.2,999012/31/2023
0.03459 % Turpin (Dennis)1,28002/9/2024
1
2
3
4

Aeterna Zentaris Executives and Management Board

Dr. Klaus Paulini
Aeterna Zentaris President, Chief Executive Officer, Director and Managing Director - AEZS Germany
Compensation 583,973
Dr. Matthias Gerlach
Aeterna Zentaris Senior Vice President - Manufacturing and Supply Chain
Compensation 292,558
Mr. Giuliano La Fratta
Aeterna Zentaris Chief Financial Officer, Senior Vice President
Compensation 267,319
Dr. Carolyn Egbert
Aeterna Zentaris Non-Executive Independent Chairman of the Board
Compensation 202,400
Mr. Dennis Turpin
Aeterna Zentaris Independent Director (since 2007)
Compensation 176,917
1
2

Aeterna Zentaris Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Nippon Kayaku Stock
Nippon Kayaku
SupplierCustomer0,680,770,610,640,02-0,08
Novo Nordisk B Stock
Novo Nordisk B
SupplierCustomer0,390,81-0,26-0,28-0,79-0,36
1

Most common questions regarding Aeterna Zentaris

What values and corporate philosophy does Aeterna Zentaris represent?

Aeterna Zentaris Inc represents values of innovation, integrity, and a commitment to improving patient outcomes. The company's corporate philosophy revolves around developing novel therapeutics for unmet medical needs. Aeterna Zentaris Inc aims to provide value for shareholders by advancing its pipeline of pharmaceutical products and maximizing commercial opportunities. With a focus on research and development, the company strives to deliver high-quality treatments that address significant medical challenges. By embracing cutting-edge science and partnering with key stakeholders, Aeterna Zentaris Inc aims to make a positive impact on the healthcare industry and the lives of patients worldwide.

In which countries and regions is Aeterna Zentaris primarily present?

Aeterna Zentaris Inc is primarily present in the United States and Canada.

What significant milestones has the company Aeterna Zentaris achieved?

Some significant milestones achieved by Aeterna Zentaris Inc. include the acquisition of rights to develop and commercialize Macrilen™, a diagnostic agent for adult growth hormone deficiency, in the United States and Canada. The company also received FDA approval for Macrilen™, which marked an important regulatory milestone. Additionally, Aeterna Zentaris Inc. successfully completed a Phase 3 clinical study for Zoptrex™ (zoptarelin doxorubicin), a potential treatment for endometrial cancer, demonstrating positive results. These achievements reflect the company's commitment to advancing innovative therapies and expanding its product portfolio.

What is the history and background of the company Aeterna Zentaris?

Aeterna Zentaris Inc., a biopharmaceutical company, was founded in 1990 and is headquartered in Canada. With a focus on developing innovative treatments in oncology, endocrinology, and other therapeutic areas, Aeterna Zentaris aims to improve the lives of patients worldwide. Through comprehensive research and development efforts, the company has successfully advanced several drug candidates, addressing unmet medical needs. Aeterna Zentaris Inc. has built a strong portfolio of potential treatment options, including Macrilen™ for growth hormone deficiency in adults. Continually striving for medical advancements, Aeterna Zentaris Inc. remains dedicated to improving patient outcomes and addressing critical healthcare challenges.

Who are the main competitors of Aeterna Zentaris in the market?

The main competitors of Aeterna Zentaris Inc in the market include pharmaceutical companies like Novartis, Pfizer, and Bristol-Myers Squibb.

In which industries is Aeterna Zentaris primarily active?

Aeterna Zentaris Inc is primarily active in the pharmaceutical industry.

What is the business model of Aeterna Zentaris?

Aeterna Zentaris Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies for various diseases. The company's business model revolves around conducting research and development activities to discover and develop novel treatments. Aeterna Zentaris Inc aims to address unmet medical needs and improve patients' lives through the development of innovative drugs. With a strong focus on oncology and endocrinology, the company combines scientific expertise and strategic partnerships to advance its pipeline of promising drug candidates. Aeterna Zentaris Inc strives to bring effective and life-changing therapies to market, ensuring better healthcare outcomes for patients worldwide.

What is the P/E ratio of Aeterna Zentaris 2024?

The Aeterna Zentaris P/E ratio is -0.35.

What is the P/S ratio of Aeterna Zentaris 2024?

The Aeterna Zentaris P/S ratio is 1.02.

What is the AlleAktien quality score of Aeterna Zentaris?

The AlleAktien quality score for Aeterna Zentaris is 3/10.

What is the revenue of Aeterna Zentaris 2024?

The expected Aeterna Zentaris revenue is 4.39 M USD.

How high is the profit of Aeterna Zentaris 2024?

The expected Aeterna Zentaris profit is -12.72 M USD.

What is the business model of Aeterna Zentaris

Aeterna Zentaris Inc. is a biopharmaceutical company based in Canada that focuses on the development and commercialization of drugs for the treatment of cancer and other serious diseases. The company operates in three core business areas: oncology, endocrinology, and hematology. In the oncology field, Aeterna Zentaris has several products in the pipeline for the treatment of gastric cancer and prognostically unfavorable breast cancer. The company also has a diagnostic test kit called Macrilen® for stimulating growth hormone in adults to diagnose growth hormone deficiency. In the endocrinology field, Aeterna Zentaris is a leader in the development of peptide-based drugs for the treatment of hormonal disorders. The company has two main products in the pipeline: Macimorelin, a diagnostic test kit for stimulating growth hormone in children, and Zoptrex, a drug for the treatment of endometriosis. In the hematology field, Aeterna Zentaris focuses on developing therapies for the treatment of serious blood disorders such as leukemia and non-Hodgkin lymphoma. The company has several products in the pipeline, including AEZS-142, a drug currently being studied in a phase 3 clinical trial for the treatment of lymphomas. Aeterna Zentaris has a clinical development platform based on the identification of peptide-based drugs and other potential compounds. The company utilizes this platform to develop innovative therapies for the treatment of cancer and other serious diseases. The business model of Aeterna Zentaris is based on leveraging different areas such as oncology, endocrinology, and hematology to develop and market innovative peptide-based drugs for the treatment of cancer and blood disorders. The capture of powerful and meaningful data through targeted clinical studies enables the company to advance its pipeline of drug developments and offer potential customers a wide range of products in various therapeutic areas. Overall, Aeterna Zentaris is an emerging biopharmaceutical company with a strong focus on innovative treatment options for serious diseases. The company is committed to advancing the exploration of peptide therapeutics in disease areas such as endocrinology, oncology, and hematology through the further development of its portfolio of clinical development programs.

What is the Aeterna Zentaris dividend?

Aeterna Zentaris pays a dividend of 0 USD distributed over payouts per year.

How often does Aeterna Zentaris pay dividends?

The dividend cannot currently be calculated for Aeterna Zentaris or the company does not pay out a dividend.

What is the Aeterna Zentaris ISIN?

The ISIN of Aeterna Zentaris is CA0079754028.

What is the Aeterna Zentaris WKN?

The WKN of Aeterna Zentaris is A1439Z.

What is the Aeterna Zentaris ticker?

The ticker of Aeterna Zentaris is AEZS.TO.

How much dividend does Aeterna Zentaris pay?

Over the past 12 months, Aeterna Zentaris paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aeterna Zentaris is expected to pay a dividend of 0 USD.

What is the dividend yield of Aeterna Zentaris?

The current dividend yield of Aeterna Zentaris is .

When does Aeterna Zentaris pay dividends?

Aeterna Zentaris pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aeterna Zentaris?

Aeterna Zentaris paid dividends every year for the past 0 years.

What is the dividend of Aeterna Zentaris?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aeterna Zentaris located?

Aeterna Zentaris is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aeterna Zentaris kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aeterna Zentaris from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Aeterna Zentaris pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Aeterna Zentaris in the year 2023?

In the year 2023, Aeterna Zentaris distributed 0 USD as dividends.

In which currency does Aeterna Zentaris pay out the dividend?

The dividends of Aeterna Zentaris are distributed in USD.

All fundamentals about Aeterna Zentaris

Our stock analysis for Aeterna Zentaris Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aeterna Zentaris Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.